Reading from the Same Playbook
This article was originally published in RPM Report
Executive Summary
Commissioner Hamburg and Rep. Rosa DeLauro draw on siimilar themes--and similar words--in making the case for regulatory science.
You may also be interested in...
Sustainable Funding for Regulatory Science: FDA, Industry Hope Fourth Time is the Charm
FDA is trying one more time to secure significant resources to fund regulatory science. FDA's leadership is making good progress with key figures in the Administration and on the Hill-but the money still isn't there.
The $4 Million NDA: US FDA User Fees After 30 Years
The cost of filing a New Drug Application with the US FDA has pushed above the $4 million mark. That is a remarkable rate of increase from the original $100,000 fee set in 1992 – but it does buy a lot more.